Phase 3 RCT of C5a-Specific Vilobelimab in Severe COVID-19 Pneumonia
A. Vlaar (Amsterdam, Netherlands), G. Hermans (Leuven, Belgium), M. Witzenrath (Berlin, Germany), P. Van Paassen (Maastricht, Netherlands), L. Heunks (Amsterdam, Netherlands), B. Mourvillier (Reims, France), S. De Bruin (Amsterdam, Netherlands), E. Lim (Amsterdam, Netherlands), M. Piagnerelli (Charleroi, Belgium), A. Roquilly (Nantes, France), J. Lascarrou (Nantes, France), M. Bauer (Jena, Germany), C. Schwebel (Grenoble, France), M. Brouwer (Amsterdam, Netherlands), P. Tuinman (Amsterdam, Netherlands), T. Welte (Hannover, Germany), G. Marx (Leuven, Belgium), U. Jaschinski (Augsburg, Germany), A. Cornet (Enschede, Netherlands), A. Grebenyuk (Barnaul, Russian Federation), P. Jorens (Antwerp, Belgium), S. Rückinger (Munich, Germany), K. Pilz (Jena, Germany), C. Thielert (Jena, Germany), D. Neukirchen (Jena, Germany), L. Ruckerbauer (Munich, Germany), B. Burnett (Ann Arbor, United States), R. Guo (Ann Arbor, United States), D. Van De Beek (Amsterdam, Netherlands), N. Riedemann (Jena, Germany)
Source: International Congress 2022 – ALERT 3: COVID and interstitial lung diseases??
Session: ALERT 3: COVID and interstitial lung diseases??
Session type: Clinical trials session
Number: 2881
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Vlaar (Amsterdam, Netherlands), G. Hermans (Leuven, Belgium), M. Witzenrath (Berlin, Germany), P. Van Paassen (Maastricht, Netherlands), L. Heunks (Amsterdam, Netherlands), B. Mourvillier (Reims, France), S. De Bruin (Amsterdam, Netherlands), E. Lim (Amsterdam, Netherlands), M. Piagnerelli (Charleroi, Belgium), A. Roquilly (Nantes, France), J. Lascarrou (Nantes, France), M. Bauer (Jena, Germany), C. Schwebel (Grenoble, France), M. Brouwer (Amsterdam, Netherlands), P. Tuinman (Amsterdam, Netherlands), T. Welte (Hannover, Germany), G. Marx (Leuven, Belgium), U. Jaschinski (Augsburg, Germany), A. Cornet (Enschede, Netherlands), A. Grebenyuk (Barnaul, Russian Federation), P. Jorens (Antwerp, Belgium), S. Rückinger (Munich, Germany), K. Pilz (Jena, Germany), C. Thielert (Jena, Germany), D. Neukirchen (Jena, Germany), L. Ruckerbauer (Munich, Germany), B. Burnett (Ann Arbor, United States), R. Guo (Ann Arbor, United States), D. Van De Beek (Amsterdam, Netherlands), N. Riedemann (Jena, Germany). Phase 3 RCT of C5a-Specific Vilobelimab in Severe COVID-19 Pneumonia. 2881
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|